UY35508A - Derivados de oxopiridina sustituidos - Google Patents

Derivados de oxopiridina sustituidos

Info

Publication number
UY35508A
UY35508A UY0001035508A UY35508A UY35508A UY 35508 A UY35508 A UY 35508A UY 0001035508 A UY0001035508 A UY 0001035508A UY 35508 A UY35508 A UY 35508A UY 35508 A UY35508 A UY 35508A
Authority
UY
Uruguay
Prior art keywords
substituted
derivatives
oxopiridine
diseases
well
Prior art date
Application number
UY0001035508A
Other languages
English (en)
Spanish (es)
Inventor
Gerdes Dr Christoph
Dr Stefan Heitmeier
Röhrig Dr Susanne
Schlemmer Dr Karl-Heinz
Dr Hartmut Schirok
Klar Dr Jürgen
Tersteegen Dr Adrian
Schäfer Dr Martina
Hillisch Prof Dr Alexander
Strassburger Julia
Schmidt Dr Martina Victoria
Buchmüller Dr Anja
Kinzel Dr Tom
Teller Dr Henrik
Jimenez Nunez Dr Eloisa
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of UY35508A publication Critical patent/UY35508A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Epidemiology (AREA)
UY0001035508A 2013-03-28 2014-03-27 Derivados de oxopiridina sustituidos UY35508A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13161588 2013-03-28
EP13190944 2013-10-30

Publications (1)

Publication Number Publication Date
UY35508A true UY35508A (es) 2014-10-31

Family

ID=50390087

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035508A UY35508A (es) 2013-03-28 2014-03-27 Derivados de oxopiridina sustituidos

Country Status (25)

Country Link
US (3) US9434690B2 (enExample)
EP (1) EP2978756B1 (enExample)
JP (2) JP6266086B2 (enExample)
KR (1) KR20150137095A (enExample)
CN (2) CN105164122B (enExample)
AP (1) AP2015008782A0 (enExample)
AU (1) AU2014242971B2 (enExample)
BR (1) BR112015024414A2 (enExample)
CA (1) CA2908085C (enExample)
CL (1) CL2015002855A1 (enExample)
CR (1) CR20150476A (enExample)
DO (1) DOP2015000246A (enExample)
EA (1) EA028034B9 (enExample)
ES (1) ES2731819T3 (enExample)
MX (1) MX2015013437A (enExample)
NI (1) NI201500143A (enExample)
PE (1) PE20151758A1 (enExample)
PH (1) PH12015502249A1 (enExample)
SG (2) SG11201506879RA (enExample)
TN (1) TN2015000434A1 (enExample)
TW (1) TWI633089B (enExample)
UA (1) UA115902C2 (enExample)
UY (1) UY35508A (enExample)
WO (1) WO2014154794A1 (enExample)
ZA (1) ZA201507155B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6479763B2 (ja) 2013-03-25 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
NO2760821T3 (enExample) 2014-01-31 2018-03-10
ES2784841T3 (es) 2014-01-31 2020-10-01 Bristol Myers Squibb Co Macrociclos con grupos aromáticos P2' como inhibidores del factor XIa
CN105829298B (zh) * 2014-02-14 2019-02-01 四川海思科制药有限公司 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
JP6526796B2 (ja) 2014-09-04 2019-06-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｆｘｉａ阻害剤であるジアミドマクロ環
ES2694189T3 (es) 2014-09-24 2018-12-18 Bayer Pharma Aktiengesellschaft Derivados de oxopiridina sustituidos
US10138236B2 (en) 2014-09-24 2018-11-27 Bayer Pharma Aktiengesellschaft Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives
ES2722423T3 (es) 2014-09-24 2019-08-12 Bayer Pharma AG Derivados de oxopiridina sustituidos
EP3197872B1 (de) 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft (2h)-2-oxopyridine als faktor xia-inhibitoren zur behandlung von thrombotischen erkrankungen
EP3197880B1 (de) 2014-09-24 2018-10-24 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate mit anti-inflammatorischer und anti-thrombotischer wirkung
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
HK1247615A1 (zh) * 2015-03-19 2018-09-28 Bayer Pharma Aktiengesellschaft 作为治疗血栓形成的因子xia抑制剂的氧代吡啶衍生物
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
US20180250280A1 (en) 2015-09-04 2018-09-06 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
FR3046791B1 (fr) * 2016-01-18 2020-01-10 Adisseo France S.A.S. Procede de preparation d'analogues de la methionine
RU2742771C2 (ru) * 2016-08-31 2021-02-10 Цзянсу Хэнжуй Медицин Ко., Лтд. Производное оксопиколинамида, способ его получения и его фармацевтическое применение
CN110193012B (zh) * 2018-02-27 2022-02-08 江苏恒瑞医药股份有限公司 一种氧代吡啶酰胺类衍生物的药物组合物及其制备方法
US11760701B2 (en) 2018-02-27 2023-09-19 The Research Foundation For The State University Of New Yrok Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
MX394495B (es) * 2018-02-27 2025-03-24 Jiangsu Hengrui Medicine Co Forma cristalina del derivado de oxopicolinamida y metodo de preparacion del mismo
PT3765452T (pt) 2018-03-15 2022-06-23 Bayer Pharma AG Processo preparativo de dois derivados de 4-{[(2s)-2-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2h)-il}butanoil]amino}-2-fluorbenzamida
BR112020018237A2 (pt) 2018-04-10 2020-12-29 Bayer Pharma Aktiengesellschaft Derivado de oxipiridina substituída
BR112021009435A2 (pt) * 2018-12-21 2021-08-17 Bayer Aktiengesellschaft derivados de oxopiridina substituída
CA3124296A1 (en) 2018-12-21 2020-06-25 Bayer Aktiengesellschaft Substituted oxopyridine derivatives
CN112047931B (zh) * 2019-06-06 2024-03-08 上海美悦生物科技发展有限公司 FXIa凝血因子抑制剂、其药物组合物和用途
CN112341377B (zh) * 2019-08-09 2024-05-14 上海美悦生物科技发展有限公司 一种杂环类化合物及其应用
GB201911816D0 (en) * 2019-08-16 2019-10-02 Univ London Queen Mary Treatment
CN114206854B (zh) * 2019-09-27 2023-02-24 深圳信立泰药业股份有限公司 FXIa抑制剂及其制备方法和医药用途
CN112940431B (zh) * 2021-02-04 2023-03-10 四川大学 一种激光诱导的荧光发射组合物及图案化荧光发射方法
CN115108977B (zh) * 2021-03-19 2024-11-29 南京正大天晴制药有限公司 一种瑞戈非尼的制备方法
CN114920699B (zh) * 2022-05-31 2024-03-19 甘肃皓天科技股份有限公司 一种制备6-氯-2-甲基-2h-吲唑-5-胺的方法
CN116262740A (zh) * 2022-11-18 2023-06-16 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
WO2024251276A1 (zh) 2023-06-09 2024-12-12 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体和应用
CN116874469B (zh) * 2023-09-06 2023-11-10 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01011805A (es) * 1999-05-19 2003-09-04 Pharmacia Corp Aril y heteroaril piridonas policiclicas, substituidas utiles para la inhibicion selectiva de la cascada de coagulacion.
PE20060285A1 (es) * 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US7361672B2 (en) * 2004-12-23 2008-04-22 Hoffmann-La Roche Inc. Heteroarylacetamide inhibitors of factor Xa
KR20090010098A (ko) * 2006-05-05 2009-01-28 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자 저해제
JP5419706B2 (ja) * 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
WO2011077711A1 (ja) * 2009-12-22 2011-06-30 興和株式会社 新規な２－ピリドン誘導体及びこれを含有する医薬
IN2014CN04676A (enExample) * 2011-12-21 2015-09-18 Ono Pharmaceutical Co
EP2882734B1 (en) * 2012-08-03 2016-10-12 Bristol-Myers Squibb Company Dihydropyridone as factor xia inhibitors
EP2978425B1 (en) * 2013-03-27 2017-09-27 Merck Sharp & Dohme Corp. Factor xia inhibitors
TWI633089B (zh) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物

Also Published As

Publication number Publication date
EP2978756A1 (de) 2016-02-03
TN2015000434A1 (en) 2017-01-03
EA201591874A1 (ru) 2016-04-29
WO2014154794A1 (de) 2014-10-02
AU2014242971A1 (en) 2015-10-15
AP2015008782A0 (en) 2015-10-31
EP2978756B1 (de) 2019-03-27
US9434690B2 (en) 2016-09-06
TWI633089B (zh) 2018-08-21
US9822102B2 (en) 2017-11-21
EA028034B9 (ru) 2018-02-28
CN108164513B (zh) 2021-05-07
US20180086742A1 (en) 2018-03-29
KR20150137095A (ko) 2015-12-08
JP6633045B2 (ja) 2020-01-22
JP6266086B2 (ja) 2018-01-24
UA115902C2 (uk) 2018-01-10
MX2015013437A (es) 2016-05-18
CN105164122A (zh) 2015-12-16
BR112015024414A2 (pt) 2017-07-18
CN105164122B (zh) 2018-02-02
JP2018065856A (ja) 2018-04-26
CN108164513A (zh) 2018-06-15
PH12015502249A1 (en) 2016-02-01
HK1218749A1 (zh) 2017-03-10
SG10201710895UA (en) 2018-02-27
CL2015002855A1 (es) 2016-08-26
ES2731819T3 (es) 2019-11-19
US20160368903A1 (en) 2016-12-22
EA028034B1 (ru) 2017-09-29
US20160052884A1 (en) 2016-02-25
NI201500143A (es) 2016-02-16
PE20151758A1 (es) 2015-12-04
JP2016515562A (ja) 2016-05-30
DOP2015000246A (es) 2015-11-15
CA2908085A1 (en) 2014-10-02
US10183932B2 (en) 2019-01-22
ZA201507155B (en) 2017-01-25
TW201524957A (zh) 2015-07-01
CR20150476A (es) 2016-02-05
AU2014242971B2 (en) 2018-07-05
CA2908085C (en) 2021-12-28
SG11201506879RA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
UY35508A (es) Derivados de oxopiridina sustituidos
ECSP18001308A (es) Derivados de oxopiridina sustituidos
PH12015501703A1 (en) Trifluormethyl-substituted ring-fused pyrimidines and use thereof
BR112017005109A2 (pt) produto refratário com base em al2o3, composição de matérias-primas para a fabricação do produto, método para a fabricação de um produto refratário, produto refratário, e emprego do produto refratário
DOP2009000285A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulacion sanguinea.
ECSP11011483A (es) Piperidinas sustituidas
MX2020013096A (es) Rutas semi-sinteticas para compuestos organicos.
CR20110627A (es) Piperidinas sustituidas
MX2016012758A (es) Composicion hiperosmolar de acido hialuronico.
UY35610A (es) Derivados de prodroga de triazolpiridinas sustituidas
CU20150164A7 (es) Benzoxazoles sustituidos
CU24278B1 (es) Derivados de oxopiridina sustituida empleados en trastornos cardiovasculares
RS20130487A1 (en) TREE
TH1401003731A (th) กระบวนการสำหรับการผลิตของ 1,3-บิวทาไดอีน
MX2015009114A (es) Proceso para preparar 5-fluoro-1-metil-3-difluorometil-1h-pirazol- 4-carbaldehido.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211206